RISK OF FRACTURES IN PATIENTS TAKING PSYCHOTROPIC DRUGS (TAKKOUCHE ET AL.)

Brendan McIntosh; Michelle Clark; Carolyn Spry

Drug Class

Fixed Effects
RR (95% CI)

Random Effects
RR (95% CI)

Number of
Studies

Benzodiazepines

All studies

1.29 (1.24 to 1.35)

1.34 (1.24 to 1.45)

Short-term benzodiazepine

1.24 (1.16 to 1.33)

1.25 (1.14 to 1.37)

Long-term benzodiazepine

1.29 (1.21 to 1.38)

1.31 (1.20 to 1.43)

Cohort studies

1.30 (1.18 to 1.43)

1.31 (1.18 to 1.45)

All case-control studies

1.29 (1.23 to 1.35)

1.36 (1.23 to 1.51)

Population-based case-control

1.28 (1.22 to 1.34)

1.33 (1.20 to 1.49)

Hospital-based case-control

1.47 (1.22 to 1.78)

1.46 (1.09 to 1.96)

Hip fractures

1.29 (1.23 to 1.36)

1.38 (1.24 to 1.54)

Antidepressants

All studies

1.53 (1.48 to 1.58)

1.60 (1.38 to 1.86)

Cohort studies

1.28 (1.04 to 1.58)

All case-control studies

1.54 (1.49 to 1.59)

1.66 (1.41 to 1.96)

Population-based case-control

1.40 (1.35 to 1.45)

1.54 (1.25 to 1.90)

Hospital-based case-control

1.90 (1.79 to 2.01)

1.88 (1.73 to 2.04)

SSRI antidepressant

1.84 (1.72 to 1.96)

1.91 (1.43 to 2.55)

Non-SSRI antidepressant

1.32 (1.26 to 1.38)

1.44 (1.27 to 1.63)

Tricyclic antidepressant

1.31 (1.25 to 1.38)

1.58 (1.24 to 2.00)

Hip fracture

1.54 (1.49 to 1.59)

1.68 (1.44 to 1.96)

Additional drug classes^*

Non-barbiturate antiepileptic drugs

1.19 (1.16 to 1.23)

1.54 (1.24 to 1.93)

Barbiturate antiepileptic drugs

3.19 (2.29 to 3.41)

2.17 (1.35 to 3.50)

Antipsychotics

1.46 (1.34 to 1.59)

1.59 (1.27 to 1.98)

Hypnotics

1.47 (1.40 to 1.54)

1.15 (0.94 to 1.39)

Opioids

1.32 (1.24 to 1.40)

1.38 (1.11 to 1.67)

You are permitted to make copies of this document for non-commercial purposes provided it is not modified when reproduced and appropriate credit is given to CADTH.

Links: This document may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites.

Industry: The following manufacturers were provided with an opportunity to comment on an earlier version of this report: Sepracor Pharmaceuticals Inc., Hoffmann-La Roche Ltd., and Pfizer Canada Inc. All comments that were received were considered when preparing the final report.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK174558

Contents

< Prev Next >

Bookshelf

Benzodiazepines in Older Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].

APPENDIX 4RISK OF FRACTURES IN PATIENTS TAKING PSYCHOTROPIC DRUGS (TAKKOUCHE ET AL.)¹⁰

Views

Other titles in this collection

Recent Activity